Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Pulmonary Embolism – Pipeline Review, H1 2015” to its store. The report provides an overview of the Pulmonary Embolism’s therapeutic pipeline.

Pulmonary Embolism Therapeutic Pipeline Review H1 2015

Pulmonary Embolism Therapeutic Pipeline Review H1 2015

Past News Releases

RSS

The report “Pulmonary Embolism – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Pulmonary Embolism. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pulmonary-embolism-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. Companies discussed in this Pulmonary Embolism – Pipeline Review, H1 2015 report include Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited and F. Hoffmann-La Roche Ltd.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are apixaban, edoxaban tosylate, rivaroxaban, Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders, SMTP-7 and TRX-1. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=365337 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 62, Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 63, Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 64, Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 65, Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 66, Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 66, Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 68, May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 69, Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention 69 and Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 70.

List of Tables
Number of Products under Development for Pulmonary Embolism, H1 2015 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 26
Pulmonary Embolism Therapeutics - Recent Pipeline Updates, H1 2015 39
Pulmonary Embolism - Dormant Projects, H1 2015 60
Pulmonary Embolism - Discontinued Products, H1 2015 61

List of Figures
Number of Products under Development for Pulmonary Embolism, H1 2015 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

Explore more reports on Pulmonary Embolism industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/pulmonary-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website